Blue Jean Financial LLC Buys New Position in Tempus AI, Inc. $TEM

Key Points

• Blue Jean Financial acquired 44,968 Tempus AI shares worth approximately $3.68 million, making TEM about 2.2% of its portfolio. Institutional investors and hedge funds collectively own 24.22% of the company.
• Analyst sentiment is mixed: 11 analysts rate the stock a Buy, nine rate it Hold, and two rate it Sell. The consensus rating is Hold, with an average price target of $72.37.
• Tempus AI shares opened at $66.75, while the company’s latest quarterly results beat expectations with a loss of $0.04 per share versus the $0.14 estimate and revenue of $382.49 million. Insiders sold $80.4 million in stock over the past 90 days, primarily through pre-arranged trading plans.

Blue Jean Financial LLC acquired a new stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 44,968 shares of the company's stock, valued at approximately $3,683,000. Tempus AI makes up about 2.2% of Blue Jean Financial LLC's portfolio, making the stock its 9th largest holding.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Generali Investments Management Co LLC bought a new stake in shares of Tempus AI during the 3rd quarter worth approximately $502,000. IFP Advisors Inc boosted its stake in Tempus AI by 44.1% in the third quarter. IFP Advisors Inc now owns 3,687 shares of the company's stock valued at $302,000 after buying an additional 1,128 shares in the last quarter. Cyndeo Wealth Partners LLC grew its position in Tempus AI by 6.7% in the third quarter. Cyndeo Wealth Partners LLC now owns 6,412 shares of the company's stock valued at $525,000 after acquiring an additional 400 shares during the last quarter. V Square Quantitative Management LLC bought a new position in Tempus AI in the third quarter valued at about $27,000. Finally, Mather Group LLC. bought a new position in Tempus AI in the third quarter valued at about $79,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TEM. Needham & Company LLC restated a "buy" rating and set a $75.00 price target on shares of Tempus AI in a report on Friday, July 31st. Freedom Capital upgraded shares of Tempus AI to a "hold" rating in a report on Tuesday, June 30th. Rothschild & Co Redburn initiated coverage on shares of Tempus AI in a research report on Tuesday, September 8th. They set a "neutral" rating and a $67.00 target price on the stock. Canaccord Genuity Group boosted their target price on shares of Tempus AI from $80.00 to $95.00 and gave the stock a "buy" rating in a report on Monday, October 12th. Finally, HC Wainwright upped their price target on shares of Tempus AI from $56.00 to $66.00 and gave the company a "buy" rating in a research report on Friday, September 11th. Eleven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $72.37.

Insider Activity at Tempus AI

In related news, CAO Ryan M. Bartolucci sold 7,062 shares of the stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $75.00, for a total transaction of $529,650.00. Following the sale, the chief accounting officer owned 60,804 shares of the company's stock, valued at approximately $4,560,300. This represents a 10.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 700 shares of the company's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $70.00, for a total value of $49,000.00. Following the sale, the chief executive officer owned 15,874 shares in the company, valued at approximately $1,111,180. This represents a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,280,965 shares of company stock worth $80,397,564 in the last ninety days. Insiders own 24.26% of the company's stock.

Tempus AI Trading Up 3.7%

TEM opened at $66.75 on Wednesday. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $93.46. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The company has a market cap of $12.04 billion, a P/E ratio of -46.35 and a beta of 3.54. The company has a fifty day moving average price of $68.47 and a two-hundred day moving average price of $56.86.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. The company's quarterly revenue was up 21.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.22) earnings per share. Analysts predict that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.